The Coalition for Epidemic Preparedness Innovations (CEPI) has expanded its collaboration with China-based Sichuan Clover Biopharmaceuticals to speed-up the development and manufacture of Covid-19 vaccine candidate.

As part of the expanded alliance, CEPI will provide an additional $66m upfront for immediate funding of preclinical studies, to carry out Phase I clinical trials and prepare sites worldwide for an efficacy trial.

The investment will also support scaling up of Clover’s manufacturing capacity to potentially produce millions of doses annually.